NIAID awards $44m contract to advance COVID-19 drug
The US institute has given a new contract to drug developer BioCryst to explore use of galidesivir in treatment of non-hospitalized COVID-19 patients.
The US institute has given a new contract to drug developer BioCryst to explore use of galidesivir in treatment of non-hospitalized COVID-19 patients.
The company intends to enable pharma and biotech companies to have greater access to cryo-electronic microscopy for their research projects.
A recent study from healthcare insights company Sermo shares information and perspectives that trial and pharma professionals could learn from.